iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch

nopparit/iStock via Getty Images iTeos Therapeutics (NASDAQ:ITOS) is gearing up to report results from several of its programs in 2024. I believe that investors can benefit here, because there is potential with multiple shots on goal. Especially, with respect to the fact that there are two protein targets which have been validated to do well in targeting patients with cancers. Having said that, this company's pipeline is not solely only built around the targeting of TIGIT protein with Belrestotug [EOS-448] ...